Carterra® CEO, Josh Eckman, Recognized as a Rising Star by the David Eccles School of Business
SALT LAKE CITY (PRWEB) June 07, 2018 -- Carterra® Inc., a provider of innovative drug discovery technologies, announced that its CEO, Josh Eckman, has been honored as a Rising Star by The University of Utah David Eccles School of Business during its 2018 Hall of Fame induction ceremony.
Josh Eckman co-founded Carterra, formerly Wasatch Microfluidics, in 2004 with Professors Bruce Gale, Jim Smith, and David Chang-Yen, as a spin-out from The University of Utah Mechanical Engineering Department. The company has been devoted to developing highly parallel microfluidic devices for drug discovery and life science research applications.
Josh and the Carterra team successfully developed, patented, and commercialized the Continuous Flow Microspotter (CFM) which uses a network of microchannels to enable flow-based array printing of proteins and antibodies on sensor surfaces. In addition, they coupled the CFM with label-free Surface Plasmon Resonance (SPR) technology to deliver high-resolution data for biotherapeutics applications at throughputs up to 100 times faster than existing platforms, compressing months of work into days and addressing a significant bottleneck in drug discovery.
Under Josh’s leadership, the Company recently raised $10M from Telegraph Hill Partners and launched the second generation, fully integrated LSA™ Array Surface Plasmon Resonance (Array SPR) instrument based on the Company’s core CFM technology.
“It is a great honor to receive this award which highlights Carterra’s success in the development and commercialization of our unique technologies,” Josh said after receiving his award. “We are seeing significant interest in the LSA from pharmaceutical and biotechnology customers due to the game-changing throughput and data that it provides in biotherapeutic drug discovery.”
The LSA has been specifically designed to address the previously unmet need for high throughput, comprehensive screening and characterization of the large mAb libraries that are now standard in biotherapeutic discovery. The LSA integrates Carterra’s patented microfluidics with proven SPR real-time detection and industry-leading software to deliver up to 100 times the throughput, in 10% of the time while requiring only 1% of the sample compared to existing instruments. This enhanced productivity enables LSA customers to expand their intellectual property coverage by gaining a more detailed understanding of the mAb epitope diversity within their libraries. Furthermore, by comprehensively screening all their mAbs rather than testing a subset or triaging based on incomplete data, they reduce the risk of missing novel, high-value biotherapeutic candidates.
About Carterra® Inc.
Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra’s high throughput LSA™ instrument for monoclonal antibody (mAb) discovery and characterization combines patented microfluidics technology with real-time array Surface Plasmon Resonance (SPR) and industry leading data analysis and visualization software, delivering up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing platforms. The LSA provides customers with mAb characterization throughput and functionality that matches the output from state-of-the-art antibody expression platforms. This enables all antibodies to be rapidly and comprehensively screened early in the discovery process so that unique epitopes and potential novel therapeutic candidates can be identified, while expanding and enhancing IP coverage.
info(at)carterra-bio.com
https://carterra-bio.com/
For further information, please contact:
Julian Abery
VP Marketing
Carterra, Inc.
P: 919-724-0946
E: jabery(at)carterra-bio.com
John McKinley, Carterra Inc., https://carterra-bio.com/, +1 415-638-7121, [email protected]
Share this article